ChartMill assigns a Buy % Consensus number of 46% to EVLO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-10-18 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-07-26 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-02-15 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-16 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2022-09-09 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-08-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-08-15 | Chardan Capital | Maintains | Buy |
| 2021-11-02 | JMP Securities | Maintains | Market Outperform |
| 2021-11-01 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2021-06-23 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-06-23 | JMP Securities | Maintains | Market Outperform |
| 2021-05-03 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-04-12 | Jefferies | Upgrade | Hold -> Buy |
7 analysts have analysed EVLO and the average price target is 10.2 USD. This implies a price increase of 3122.75% is expected in the next year compared to the current price of 0.3165.
The consensus rating for EVELO BIOSCIENCES INC (EVLO) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering EVELO BIOSCIENCES INC (EVLO) is 7.